Enter your terms above and click the 'Search' button.

Showing articles 0 to 8 of 8 Filter Applied: disability,neurological (Click to remove) Fat Embolism Syndrome in Sickle Cell Disease J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020 Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy Neurol 76:1697-1704, Vermersch,P.,et al, 2011 Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy Neurol 72:396-401,392, Stuve,O.,et al, 2009 Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007 Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis NEJM 354:911-923,965, Rudick,R.A.,et al, 2006 A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis NEJM 354:899-910,965, Polman,C.H.,et al, 2006 Reflex Sympathetic Dystrophy BMJ 310:1645-1648, Paice,E., 1995 Results of the Seven-Year Prospective Study of Stroke Patients Stroke 19:942-949, Scmidt,E.V.,et al, 1988 Showing articles 0 to 8 of 8